CAS Registry Number comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
In 1905, Rafael Zerda Bayón named the active extract of ayahuasca as telepathine, a name latter used by the Colombian chemist Guillermo Fischer Cárdenas when he isolated the substance in 1932. Contemporaneously, Lewin and Gunn were independently studying the properties of the banisterine, extracted of the B. caapi, and its effects on animal models. Further clinical trials were being conducted, exploring the effects of banisterine on Parkinson's disease. Later it was found that both telepathine and banisterine are the same substance, identical to a chemical already isolated from Peganum harmala and given the name Harmine.
==== Sex differences ==== In humans, oxytocin differentially affects males and females. Females who are administered oxytocin are overall faster in responding to socially relevant stimuli than males who receive oxytocin. Additionally, after the administration of oxytocin, females show increased amygdala activity in response to threatening scenes; however, males do not show increased amygdala activation. This phenomenon can be explained by examining the role of gonadal hormones, specifically estrogen, which modulate the enhanced threat processing seen in females. Estrogen has been shown to stimulate oxytocin release from the hypothalamus and promote receptor binding in the amygdala. It has also been shown that testosterone directly suppresses oxytocin in mice. This has been hypothesized to have evolutionary significance. With oxytocin suppressed, activities such as hunting and attacking invaders would be less mentally difficult as oxytocin is strongly associated with empathy.
==== Combination drugs ==== Acecarbromal/quebracho/vitamin E (Afrodor) – various actions – erectile dysfunction Aviptadil/phentolamine (Invicorp; phentolamine/aviptadil; PSD-510; Vasopotin) – combination of aviptadil (vasoactive intestinal peptide (VIP) receptor agonist) and phentolamine (α-adrenergic receptor antagonist) – erectile dysfunction [151] Papaverine/phentolamine – combination of papaverine (phosphodiesterase PDE10A inhibitor, other actions) and phentolamine (α-adrenergic recpetor antagonist) – erectile dysfunction Tadalafil/tamsulosin (Gugutams cap.; HCP-1303) – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [152]
CLASP is an international non-profit organization specializing in the energy efficiency of appliances, equipment, and lighting. Founded in 1999, CLASP has worked in over 90 countries, and is headquartered in Washington, DC with teams and offices in Brazil, Europe, India, Indonesia, Kenya, and the United Kingdom.
== Shelf-life and safety == The purpose of IMF foods is to achieve a water activity that the food can be stored safely without refrigeration. However, the food is not sterile. Staphylococcus aureus is a microorganism of concern as it can grow and produce specific enterotoxins in water activities of 0.83-0.86 under aerobic conditions. Because of this, proper handling, storage, hygiene and good manufacturing practices are necessary to prevent Staphylococcus aureus. Molds of Aspergillis and Penicillium species can grow and produce harmful mycotoxins at water activity 0.77-0.85. Salmonella and Bacillus cereus are the primary pathogens of concern with low-moisture foods and IMFs. Most illnesses associated with low-moisture foods or IMFs have been caused by Salmonella spp. To reduce the risk of bacterial growth, products are treated with a combination of low pH, addition of sugar, salt and preservatives, and a thermal process that can eliminate pathogens and extend shelf-life. In the case of yeasts and molds, chemical preservatives such as sorbates and propionates are used to inhibit their growth.
Sources: en.wikipedia.org
{\displaystyle {\begin{array}{lll}M({\ce {NaCl}})&=[22.98976928(2)+35.453(2)]\times M_{\text{u}}\\&=58.443(2){\text{ g/mol}}\\M({\ce {C12H22O11}})&=[12\times 12.0107(8)+22\times 1.00794(7)+11\times 15.9994(3)]\times M_{\text{u}}\\&=342.297(14){\text{ g/mol}}\end{array}}}
== Awards and honors == Raphael Katzen Award, Society for Industrial Microbiology, 2009. Fellow, Class of 2008, American Society for the Advancement of Science (AAAS). Featured profile, Nature Biotechnology, November 2007. Fellow, Society of Industrial Microbiology, 2003. College of Fellows, Class of 2001, American Institute of Medical and Biological Engineering (AIMBE).
=== Third representation === Given uncontrolled flow rate or varied solvent composition, another representation was designed such that a different heating source and control system would allow for partial vaporization. Two different heating methods were combined because one is capable of more rapid response time while the other is slower. This combination allows the third representation of vaporizer to handle fluctuations in flow rate coming of the LC column.
For services to Social Enterprise and the Creative Industries. Ivora Maria Ferreria-Bean. Team Manager, Birmingham Children's Trust. For services to Children and Families. Malcolm Ernest Ferris-Lay. Trustee, Tea Trade Benevolent Society and Scottish Tartan Authority. For Charitable Service. Maxine Jane Ficarra (Maxine Purdie). Lately Chief Executive Officer, PraxisAuril. For services to Knowledge Exchange. Margaret Ruth Fingerhut. For services to Music and to Charitable Fundraising. David Edward Clarke Finlay. For services to Olympic Wrestling in Northern Ireland. Stephen Fischbacher. Founding Director, Fischy Music. For services to Mental Health and Well-Being. Alison Fordy. Proprietor, Alison Radcliffe School of Dance. For services to Young People and to the community in Middlesbrough, North Yorkshire. Alison Fotheringham. Appeals and Litigation Assistant Director, Home Office. For Public and Voluntary Service. Alison Jane France. Operational Leader, Department for Work and Pensions. For services to Disadvantaged People. Susan Elizabeth Francis. Principal Educational Psychologist and Strategic Lead for Children and Young People's Emotional Wellbeing and Mental Health, Enfield London Borough Council. For services to Children with Special Educational Needs and Disabilities. Mike Anthony Frankl. For services to Charity, to Homeless People and to the Jewish Community in Cambridge. Pamela Marguerita Frickleton. Foster Carer, Plymouth City Council. For services to Young People. Peter Thornton Frickleton. Foster Carer, Plymouth City Council. For services to Young People.
== Controversy == At the 68th AACC Annual Scientific Meeting in 2016, Elizabeth Holmes, CEO and founder of Theranos, spoke at what AACC described as a “special session.” Holmes, who the Centers for Medicare and Medicaid Services (CMS) had recently been banned from owning, operating or directing a blood testing service for a period of two years, was invited to present scientific data on her company's much discussed Edison device. Instead, Holmes took the opportunity to unveil a new product dubbed miniLab. Several people on the Theranos scientific advisory board were members of the association.
Sources: en.wikipedia.org
Svetlana Mojsov is a Yugoslav-born Macedonian American chemist who is a Lulu Chow Wang and Robin Chemers Neustein Research Professor at the Rockefeller University. Her research considers peptide synthesis. She discovered the glucagon-like peptide-1 (GLP-1) and uncovered its role in glucose metabolism and the secretion of insulin. Her breakthroughs were transformed by Novo Nordisk into therapeutic agents against diabetes and obesity.
Symptoms of intoxication from overdose include drowsiness, insomnia, stupor, agitation, coma, transient confusion, increased anxiety, ataxia, convulsions, oliguria, anuria, tachycardia or bradycardia, arrhythmia, AV block, hypotension, shock, respiratory depression, and, rarely, cardiac arrest.
== For vitamins == A number of vitamins have distinct vitamers of distinct biological potencies. There is a system in place also called the international unit to describe the relative strength of these different molecular forms. Like the biological international unit, the IU for vitamins is also an arbitrary number that cannot be interconverted among different types of activities. By 1934, the WHO (then the League of Nations Health Organisation) had already defined the international units for vitamins A, B1, C, and D. Unlike biologic preparations, small molecules like vitamins can be very easily purified to yield products that are equivalent in potency. As a result, a simple mass conversion (as opposed to an assay) suffices to obtain the IU:
==== Bone metabolism ==== In mice and humans, alterations in serotonin levels and signalling have been shown to regulate bone mass. Mice that lack brain serotonin have osteopenia, while mice that lack gut serotonin have high bone density. In humans, increased blood serotonin levels have been shown to be a significant negative predictor of low bone density. Serotonin can also be synthesized, albeit at very low levels, in the bone cells. It mediates its actions on bone cells using three different receptors. Through 5-HT1B receptors, it negatively regulates bone mass, while it does so positively through 5-HT2B receptors and 5-HT2C receptors. There is very delicate balance between physiological role of gut serotonin and its pathology. Increase in the extracellular content of serotonin results in a complex relay of signals in the osteoblasts culminating in FoxO1/ Creb and ATF4 dependent transcriptional events. Following the 2008 findings that gut serotonin regulates bone mass, the mechanistic investigations into what regulates serotonin synthesis from the gut in the regulation of bone mass have started. Piezo1 has been shown to sense RNA in the gut and relay this information through serotonin synthesis to the bone by acting as a sensor of single-stranded RNA (ssRNA) governing 5-HT production. Intestinal epithelium-specific deletion of mouse Piezo1 profoundly disturbed gut peristalsis, impeded experimental colitis, and suppressed serum 5-HT levels. Because of systemic 5-HT deficiency, conditional knockout of Piezo1 increased bone formation.
=== 1990s === The 1990s laid the groundwork for genomics and regenerative medicine. In 1990, the international Human Genome Project was officially launched with the goal of mapping and sequencing the entire human genome. The same year marked the first approved human gene therapy clinical trial, conducted by W. French Anderson to treat severe combined immunodeficiency (SCID). In 1996, researchers led by Ian Wilmut successfully cloned the first mammal from an adult somatic cell, Dolly the sheep. Shortly thereafter, in 1998, James Thomson isolated human embryonic stem cells, opening new avenues for regenerative medicine and tissue engineering.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.